Clinical Trial Update: Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating radiation plus cetuximab and an EGFR antisense DNA agent for head and neck squamous cell carcinoma; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• EGFR antisense DNA

Snippet

Sponsor: University of Pittsburgh | Conditions: Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Status: TERMINATED